Report on the Early Efficacy and Tolerability of I125 Permanent Prostate Brachytherapy from a UK Multi-institutional Database

Clinical Oncology

Volumn 20, Issue 10, 2008, Pages 738-744

  Mitchell, D M ^a   Mandall, P ^a   Bottomley, D ^b   Hoskin, P J ^c   Logue, J P ^a   Ash, D ^b   Ostler, P ^c   Elliott, T ^a   Henry, A ^b   Wylie, J P ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

Database; prostate brachytherapy; PSA

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; IODINE 125;

ADULT; AGED; ARTICLE; BLADDER CATHETERIZATION; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; UNITED KINGDOM; URINARY TRACT DISEASE;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DATABASES, FACTUAL; GREAT BRITAIN; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 55149090271     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.09.003     Document Type: Article

References (19)

1. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67 (2007) 327-333
2. Bottomley D., Ash D., Al-Qaisieh B., et al. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds. Radiother Oncol 82 (2007) 46-49
3. National Institute for Health and Clinical Excellence. Low dose rate brachytherapy for localised prostate cancer. NICE Guidance 132, July 2005.
4. Department of Health advice on the development of low dose rate (permanent seed implant) brachytherapy services for localised prostate cancer in England (Gateway Reference 7385, November 2006).
5. Ash D., Al-Qaisieh B., Gould K., Carey B., Bottomley D., and Henry A.M. Long term outcomes following iodine-125 monotherapy for localized prostate cancer: the Cookridge 10 year results. Clin Oncol 3 (2007) S18
6. Khaksar S.J., Langley S.E.M., Lovell D., and Laing R.W. Interstitial low dose rate brachytherapy for prostate cancer - a focus on intermediate- and high-risk disease. Clin Oncol 18 (2006) 513-518
7. ASTRO. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
8. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-997
9. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
10. Henderson A., Ismail A.K.A., Cunningham M., et al. Toxicity and early biochemical outcomes from 125iodine prostate brachytherapy in the UK: a prospective study. Clin Oncol 16 (2004) 95-104
11. 125I prostate brachytherapy. Brachytherapy 5 (2006) 9-13
12. Ash D., Flynn A., Battermann J., de Reijke T., Lavagnini P., and Blank L. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 57 (2000) 315-321
13. Lee W.R., deGuzman A.F., Bare R.L., Marshall M.G., and McCullough D.L. Post implant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys 46 (2000) 83-88
14. Al-Qaisieh B. Pre- and post-implant dosimetry: an inter-comparison between UK prostate brachytherapy centres. Radiother Oncol 66 (2003) 181-183
15. Crook J., Milosevic M., Catton P., et al. Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy. Brachytherapy 1 (2002) 66-73
16. Salembier C., Lavagnini P., Nickers P., et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendation on prostate brachytherapy. Radiother Oncol 83 (2007) 3-10
17. 125iodine prostate brachytherapy. Clin Oncol 18 (2006) 326-332
18. Shakespeare D., Mitchell D.M., Carey B.M., et al. Recto-urethral fistula following brachytherapy for localized prostate cancer. Colorectal Dis 9 (2006) 328-331
19. Stock R.G., Cahlon O., Cesaretti J.A., Kollmeier M.A., and Stone N.N. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 1352-1359